Abstract:Brain tumors, including primary brain tumors and central nervous system (CNS) metastases, remain among the most challenging malignancies to treat, with therapeutic options often limited by the inability of drugs to penetrate the blood-brain barrier. Poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair, and inhibition of PARP1 specifically drives synthetic lethality in BRCA-mutated disease. While they've achieved commercial success, first generation PARP inhibitors are limited in their utility as they cannot readily pass through the blood-brain barrier and have adverse side effects, likely driven by the collateral inhibition of PARP2. Development of a PARP1-selective, CNS penetrant inhibitor could reduce toxicity, while providing a new therapeutic option for brain tumors. Traditional drug discovery methods are time-consuming and costly, necessitating innovative approaches. Here, we describe the application of Deep Docking, an advanced artificial intelligence (AI) approach, to discover a novel, PARP1-selective inhibitor for use against brain tumors. Deep Docking utilizes deep learning to accelerate the prediction of the binding affinity of a large number of compounds to target proteins, streamlining the virtual screening process and allowing for rapid docking of billions of compounds against the PARP1 protein. Additionally, state-of-the-art generative algorithms and deep learning techniques for predicting drug-like properties such as metabolism, permeability, and safety profiles, can be combined to rapidly perform hit-to-lead optimization. We will present preliminary Deep Docking screening results from billions of compounds, identifying several with predicted high binding affinities for PARP-1. Validating in vitro and in vivo data, including PARP1 selectivity, metabolic stability, pharmacokinetic profile, CNS penetration and safety profile, will be described. Application of the Deep Docking AI platform is being used to significantly accelerate the discovery of a selective PARP-1 inhibitor for brain tumors. This approach will not only improve the efficiency of drug discovery but also enhance the specificity and efficacy of potential therapeutics.

Predicted Par1 Inhibitors from Multiple Computational Methods

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors

Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors

Study of PARP inhibitors for breast cancer based on enhanced multiple kernel function SVR with PSO

Dddr-15. Utilizing Deep Docking And Artificial Intelligence For The Discovery Of Novel Parp1-Selective Inhibitors For Use Against Brain Tumors

farPPI: a webserver for accurate prediction of protein-ligand binding structures for small-molecule PPI inhibitors by MM/PB(GB)SA methods

Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor

Interpretation of the Binding Affinities of PTP1B Inhibitors with the MM-GB/SA Method and the X-score Scoring Function.

Synthesis and Biological Evaluation of Piperidyl Benzimidazole Carboxamide Derivatives As Potent PARP-1 Inhibitors and Antitumor Agents

Machine Learning Models Combined with Virtual Screening and Molecular Docking to Predict Human Topoisomerase I Inhibitors

Binding Affinity and Dissociation Pathway Predictions for a Series of USP7 Inhibitors with Pyrimidinone Scaffold by Multiple Computational Methods.

Insights Into The Inhibition And Mechanism Of Compounds Against Lps-Induced Pge(2) Production: A Pathway Network-Based Approach And Molecular Dynamics Simulations

Design of Selective PARP-1 Inhibitors and Antitumor Studies

Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds

Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors

Discovery of novel PARP-1 inhibitors using tandem in silico studies: integrated docking, e-pharmacophore, deep learning based de novo and molecular dynamics simulation approach

Combined 3D-QSAR, molecular docking and molecular dynamics simulation study on pyrazole-and triazole-derived carbamates as LPAR1 antagonists